Integrated Filing — IndAS


General information about company

Scrip Code 523642
NSE Symbol PIIND
MSEI Symbol NOTLISTED
ISIN INE603J01030
Name of company PI INDUSTRIES LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-Apr-2024
Date of end of financial year 31-Mar-2025
Date of board meeting when results were approved 19-May-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 12-May-2025
Description of presentation currency INR (in Actuals)
Reporting Type Quarterly
Reporting Quarter Fourth quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Single segment
Description of single segment Agri
Start date and time of board meeting 19-May-2025   13:30:00
End date and time of board meeting 19-May-2025   18:55:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 2025-02-06
Indicate Company website link for updated RPT policy of the Company https://www.piindustries.com/wp-content/uploads/2025/02/RPT_Policy_Signed-1.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? Yes
No. of times funds raised during the quarter 1
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? Yes



Financial Results Ind-AS

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Part I Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1 Income
Revenue from operations 16482000000 75712000000
Other income 682000000 3006000000
Total income 17164000000 78718000000
2 Expenses
(a) Cost of materials consumed 7385000000 32190000000
(b) Purchases of stock-in-trade 137000000 1105000000
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade -48000000 2644000000
(d) Employee benefit expense 1389000000 5951000000
(e) Finance costs 16000000 68000000
(f) Depreciation, depletion and amortisation expense 647000000 2626000000
(f) Other Expenses
1 Net Impairment losses on financial assets 113000000 141000000
2 Power, fuel & water 609000000 2538000000
3 Repairs & maintenance 335000000 1026000000
4 Environment & pollution control expenses 281000000 1285000000
5 Advertisement & sales promotion 79000000 530000000
6 Travelling and conveyance 160000000 725000000
7 Legal & professional fees 320000000 906000000
8 Laboratory & testing charges 110000000 454000000
9 Freight & cartage 104000000 525000000
10 Other Expenses 469000000 2047000000
Total other expenses 2580000000 10177000000
Total expenses 12106000000 54761000000
3 Total profit before exceptional items and tax 5058000000 23957000000
4 Exceptional items 0 0
5 Total profit before tax 5058000000 23957000000
6 Tax expense
7 Current tax 832000000 4011000000
8 Deferred tax 368000000 1281000000
9 Total tax expenses 1200000000 5292000000
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0 0
11 Net Profit Loss for the period from continuing operations 3858000000 18665000000
12 Profit (loss) from discontinued operations before tax 0 0
13 Tax expense of discontinued operations 0 0
14 Net profit (loss) from discontinued operation after tax 0 0
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0 0
16 Total profit (loss) for period 3858000000 18665000000
17 Other comprehensive income net of taxes 336000000 -209000000
18 Total Comprehensive Income for the period 4194000000 18456000000
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 152000000 152000000
Face value of equity share capital 1 1
27 Details of debt securities
22 Reserves excluding revaluation reserve 102875000000
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 25.43 123.03
Diluted earnings (loss) per share from continuing operations 25.42 123.02
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 25.43 123.03
Diluted earnings (loss) per share from continuing and discontinued operations 25.42 123.02
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-Apr-2024
Date of end of reporting period 31-Mar-2025
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 28603000000
Capital work-in-progress 2822000000
Investment property
Goodwill 671000000
Other intangible assets 221000000
Intangible assets under development 1620000000
Biological assets other than bearer plants
Investments accounted for using equity method
Non-current financial assets
Non-current investments 20090000000
Trade receivables, non-current
Loans, non-current 0
Other non-current financial assets 2186000000
Total non-current financial assets 22276000000
Deferred tax assets (net) 0
Other non-current assets 268000000
Total non-current assets 56481000000
2 Current assets
Inventories 8372000000
Current financial asset
Current investments 12598000000
Trade receivables, current 15992000000
Cash and cash equivalents 4573000000
Bank balance other than cash and cash equivalents 18321000000
Loans, current 30000000
Other current financial assets 201000000
Total current financial assets 51715000000
Current tax assets (net) 0
Other current assets 2626000000
Total current assets 62713000000
3 Non-current assets classified as held for sale 0
4 Regulatory deferral account debit balances and related deferred tax Assets 0
Total assets 119194000000
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 152000000
Other equity 102875000000
Total equity attributable to owners of parent 103027000000
Non controlling interest
Total equity 103027000000
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 0
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0
Total Trade payable 0
Other non-current financial liabilities 625000000
Total non-current financial liabilities 625000000
Provisions, non-current 55000000
Deferred tax liabilities (net) 649000000
Deferred government grants, Non-current 0
Other non-current liabilities 0
Total non-current liabilities 1329000000
Current liabilities
Current financial liabilities
Borrowings, current 0
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 485000000
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 10528000000
Total Trade payable 11013000000
Other current financial liabilities 2488000000
Total current financial liabilities 13501000000
Other current liabilities 843000000
Provisions, current 258000000
Current tax liabilities (Net) 236000000
Deferred government grants, Current 0
Total current liabilities 14838000000
3 Liabilities directly associated with assets in disposal group classified as held for sale 0
4 Regulatory deferral account credit balances and related deferred tax liability 0
Total liabilities 16167000000
Total equity and liabilites 119194000000
Disclosure of notes on assets and liabilities



Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-Jan-2025 01-Apr-2024
Date of end of reporting period 31-Mar-2025 31-Mar-2025
Whether accounts are audited or unaudited Audited Audited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Remeasurements gain/(loss) on defined benefits plans 102000000 32000000
Total Amount of items that will not be reclassified to profit and loss 102000000 32000000
2 Income tax relating to items that will not be reclassified to profit or loss 36000000 11000000
3 Amount of items that will be reclassified to profit and loss
1 Effective portion of gain/(loss) on cash flow hedges 415000000 -353000000
Total Amount of items that will be reclassified to profit and loss 415000000 -353000000
4 Income tax relating to items that will be reclassified to profit or loss 145000000 -123000000
5 Total Other comprehensive income 336000000 -209000000



Cash flow statement, indirect

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 2024-04-01
B Date of end of reporting period 2025-03-31
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Standalone
Part I Blue color marked fields are non-mandatory.
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 23957000000
Adjustments for reconcile profit (loss)
Adjustments for finance costs 68000000
Adjustments for decrease (increase) in inventories 3296000000
Adjustments for decrease (increase) in trade receivables, current -7949000000
Adjustments for decrease (increase) in trade receivables, non-current 0
Adjustments for decrease (increase) in other current assets -183000000
Adjustments for decrease (increase) in other non-current assets 0
Adjustments for other financial assets, non-current 86000000
Adjustments for other financial assets, current 2000000
Adjustments for other bank balances 8000000
Adjustments for increase (decrease) in trade payables, current -622000000
Adjustments for increase (decrease) in trade payables, non-current 0
Adjustments for increase (decrease) in other current liabilities 1000000
Adjustments for increase (decrease) in other non-current liabilities 0
Adjustments for depreciation and amortisation expense 2626000000
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 174000000
Adjustments for provisions, current -87000000
Adjustments for provisions, non-current 0
Adjustments for other financial liabilities, current 162000000
Adjustments for other financial liabilities, non-current 24000000
Adjustments for unrealised foreign exchange losses gains -146000000
Adjustments for dividend income 0
Adjustments for interest income 2130000000
Adjustments for share-based payments 34000000
Adjustments for fair value losses (gains) -549000000
Adjustments for undistributed profits of associates 0
Other adjustments for which cash effects are investing or financing cash flow 32000000
Other adjustments to reconcile profit (loss) 0
Other adjustments for non-cash items -132000000
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0
Total adjustments for reconcile profit (loss) -5285000000
Net cash flows from (used in) operations 18672000000
Dividends received 0
Interest paid 0
Interest received 0
Income taxes paid (refund) 3887000000
Other inflows (outflows) of cash 0
Net cash flows from (used in) operating activities 14785000000
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0
Cash flows used in obtaining control of subsidiaries or other businesses 6264000000
Other cash receipts from sales of equity or debt instruments of other entities 0
Other cash payments to acquire equity or debt instruments of other entities 0
Other cash receipts from sales of interests in joint ventures 0
Other cash payments to acquire interests in joint ventures 0
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0
Proceeds from sales of property, plant and equipment 109000000
Purchase of property, plant and equipment 7179000000
Proceeds from sales of investment property 0
Purchase of investment property 0
Proceeds from sales of intangible assets 0
Purchase of intangible assets 0
Proceeds from sales of intangible assets under development 0
Purchase of intangible assets under development 0
Proceeds from sales of goodwill 0
Purchase of goodwill 0
Proceeds from biological assets other than bearer plants 0
Purchase of biological assets other than bearer plants 0
Proceeds from government grants 0
Proceeds from sales of other long-term assets 0
Purchase of other long-term assets 0
Cash advances and loans made to other parties 0
Cash receipts from repayment of advances and loans made to other parties 0
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0
Dividends received 0
Interest received 2102000000
Income taxes paid (refund) 0
Other inflows (outflows) of cash -4126000000
Net cash flows from (used in) investing activities -15358000000
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0
Payments from changes in ownership interests in subsidiaries 0
Proceeds from issuing shares 0
Proceeds from issuing other equity instruments 0
Payments to acquire or redeem entity's shares 0
Payments of other equity instruments 0
Proceeds from exercise of stock options 0
Proceeds from issuing debentures notes bonds etc 0
Proceeds from borrowings 0
Repayments of borrowings 0
Payments of lease liabilities 169000000
Dividends paid 2276000000
Interest paid 67000000
Income taxes paid (refund) 0
Other inflows (outflows) of cash 0
Net cash flows from (used in) financing activities -2512000000
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes -3085000000
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0
Net increase (decrease) in cash and cash equivalents -3085000000
Cash and cash equivalents cash flow statement at beginning of period 7658000000
Cash and cash equivalents cash flow statement at end of period 4573000000







Details of Impact of Audit Qualification

Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 Price Waterhouse Chartered Accountant LLP Yes 30-Nov-2026
2 Not applicable No


Financial details

Sr. Particulars Audited Figures (as reported before adjusting for qualifications) Adjusted Figures (audited figures after adjusting for qualifications)
1 Turnover / Total income
2 Total Expenditure
3 Net Profit/(Loss)
4 Earnings Per Share
5 Total Assets
6 Total Liabilities
7 Net Worth




Signatories detail

Name of CEO / Managing director
Name of CFO
Name of audit committee chairman
Name of statutory auditor
Name of other signatory, if any, with designation
Place
Date



Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (1)

Mode of Fund Raising QIP
Description of mode of fund raising (Applicable in case of others is selected)
Date of Raising Funds 09-Jul-2020
Amount Raised 19749660000
Report filed for Quarter ended 31-Mar-2025
Monitoring Agency Not Applicable
Monitoring Agency Name, if applicable
Is there a Deviation / Variation in use of funds raised No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders
If Yes, Date of shareholder Approval
Explanation for the Deviation / Variation NA
Comments of the Audit Committee after review Nil deviation
Comments of the auditors, if any Nil
Sr. Original Object Modified Object, if any Original Allocation Modified allocation, if any Funds Utilised Amount of Deviation/Variation for the quarter according to applicable object Remarks if any
1 To utilize the Net Proceeds for:-n(i) funding the organic or inorganic growth opportunities in the area of its operations and adjacencies,n(ii) other long-term capital requirements,n(iii) investments in Subsidiaries, joint venture(s) and affiliate(s) (either through debt or equity or any convertible securities), n(iv) pre-payment and / or repayment of outstanding borrowings and/ or,n(v) general corporate requirements or any other purposes, as may be permissible under the applicable law and approved by our Board or its duly constituted committee. Not applicable 19749660000 0 16105070000 0 Out of the total funds utilized, - Rs. 674.99 million were utilized in the quarter ended December 31, 2022, and -Rs. 190 million were utilized in the quarter ended March 31, 2023 -Rs. 7,564.99 million were utilized in the quarter ended June 30, 2023 -Rs. 100 million were utilized in the quarter ended September 30, 2023 - Rs, 390 million were utilized in the quarter ended December 31, 2023 - Rs. 920 million were utilized in the quarter ended March 31, 2024 - Rs. 4948.76 million were utilized in the quarter ended September 30, 2024 - Rs. 1316.33 million were utilized in the quarter ended December 31, 2024 - NIL million were utilized in the quarter ended March 31, 2025


Signatory Details

Name of signatory Shruti Joshi
Designation of person Company Secretary and Compliance Officer
Place Mumbai
Date 19-May-2025




Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)

Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity /subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 PI Industries Limited Jivagro Ltd Subsidiary Purchase of goods or services 0 Exempted 60350000 -21330000 -58020000
2 PI Industries Limited Jivagro Ltd Subsidiary Sale of goods or services 0 Exempted -340160000 581240000 209800000
3 PI Industries Limited Jivagro Ltd Subsidiary Any other transaction Reimbursement of Insurance Expenses 0 Exempted 0 1340000 0
4 PI Industries Limited Jivagro Ltd Subsidiary Any other transaction Rent income 0 Exempted -1640000 320000 320000
5 PI Industries Limited PI Foundation Other related party Any other transaction Contribution towards CSR Activities 290000000 Ok 143080000 0 0
6 PI Industries Limited PI Health Sciences Limited Subsidiary Any other transaction Rent income 0 Exempted -360000 190000 0
7 PI Industries Limited PI Health Sciences Limited Subsidiary Any other transaction Rent Expense 0 Exempted 1990000 0 -1790000
8 PI Industries Limited PI Health Sciences Limited Subsidiary Interest received 0 Exempted -18160000 11160000 27510000
9 PI Industries Limited PI Health Sciences Limited Subsidiary Investment 0 Exempted 1000000000 10910000000 11910000000 Investment 0.005 10 Years Unsecured For acquisition of entity, assets and Working Capital requirement etc. Textual Information(1)
10 PI Industries Limited PI Health Sciences Limited Subsidiary Any other transaction Reimbursement of Insurance Expenses 0 Exempted 0 120000 0
11 PI Industries Limited PI Health Sciences Limited Subsidiary Sale of goods or services 0 Exempted -3880000 1040000 1630000
12 PI Industries Limited PI Health Sciences Limited Subsidiary Sale of fixed assets 0 Exempted -160000 0 0
13 PI Industries Limited PI Health Sciences Limited Subsidiary Purchase of goods or services 0 Exempted 18570000 0 -9300000
14 PI Industries Limited PI Japan Co Ltd Subsidiary Purchase of goods or services 0 Exempted 30410000 -8670000 -8770000
15 PI Industries Limited PI Kumiai Private Limited Joint venture Purchase of goods or services 700000000 ok 226080000 -280720000 -208060000
16 PI Industries Limited PI Kumiai Private Limited Joint venture Sale of goods or services -500000000 ok -180000000 24050000 94470000
17 PI Industries Limited PI Kumiai Private Limited Joint venture Any other transaction Jobwork income -125000000 ok -33540000 0 16720000
18 PI Industries Limited PI Kumiai Private Limited Joint venture Any other transaction Rent income -5000000 ok -2440000 430000 1440000
19 PI Industries Limited PI Kumiai Private Limited Joint venture Any other transaction Shared Infrastructure and Shared Manpower income -9600000 ok -3230000 2800000 2700000
20 PI Industries Limited PI Life Science Research Limited Subsidiary Purchase of goods or services 0 Exempted 40940000 -9980000 -16150000
21 PI Industries Limited PI Life Science Research Limited Subsidiary Any other transaction Power and rent income 0 Exempted -1480000 270000 0
22 PI Industries Limited PI Life Science Research Limited Subsidiary Any other transaction Business Support Services 0 Exempted -30000 0 0
23 PI Industries Limited PII ESOP TRUST Controlled Trust Loan 0 Not Applicable 0 10000000 10000000
24 PI Industries Limited PILL Finance and Investment Ltd. Subsidiary Any other transaction Rent paid 0 Exempted 720000 50000 0
25 PI Industries Limited PILL Finance and Investment Ltd. Subsidiary Any other transaction Business Support Services Exempted -30000 50000 0
26 PI Industries Limited Solinnos Agro Sciences Private Limited Associate Any other transaction Rent income -500000 ok -220000 130000 -30000
27 PI Industries Limited Solinnos Agro Sciences Private Limited Associate Any other transaction Accounting fees,Manpower and other services income -4800000 ok -2120000 850000 370000
28 PI Industries Limited PI Industries Management Consultancies LLC Subsidiary Investment 0 Exempted 316330000 3948760000 4265090000
29 PI Industries Limited PI Industries Management Consultancies LLC Subsidiary Purchase of goods or services 0 Exempted 79440000 0 -79440000
30 PI Industries Limited Plant Health Care, Inc Subsidiary Any other transaction Reimbursement on account of expenditure incurred Exempted 360000 0 -360000
31 PI Industries Limited Wolkem India Ltd Entity in which director is interested Purchase of goods or services 1500000 ok 410000 -60000 -70000
32 PI Industries Limited Mrs. Madhu Singhal Promoters - Relative of Key Management Personnel Any other transaction Rent paid 2100000 ok 980000 0 0
33 PI Industries Limited Ms. Pooja Singhal Promoters - Relative of Key Management Personnel Any other transaction Rent paid 300000 ok 130000 0 0
34 PI Industries Limited Mr. Salil Singhal Promoters - Relative of Key Management Personnel Purchase of goods or services 15000000 ok 6690000 -3630000 0
35 PI Industries Limited Mr. Salil Singhal Promoters - Relative of Key Management Personnel Any other transaction Travel & Other expenditure incurred Approved on Actual by AC 8590000 5240000 0
36 PI Industries Limited Mr. Mayank Singhal Vice Chairperson & Managing Director Remuneration Within maximum limit as approved by NRC / Board 61870000 0 0
37 PI Industries Limited Mr. Mayank Singhal Vice Chairperson & Managing Director Any other transaction Travel & Other expenditure incurred Approved on Actual by Audit committee 40820000 0 0
38 PI Industries Limited Mr. Mayank Singhal Vice Chairperson & Managing Director Any other transaction Commission Within maximum limit as approved by NRC / Board 150000000 0 -150000000
39 Jivagro Ltd PI Foundation Other related party Any other transaction Contribution towards CSR Activities Ok 2740000 0 0
40 PI Industries Management Consultancies LLC Plant Health Care Limited (Erstwhile Plant Health care Plc) Subsidiary Investment 0 Exempted 0 3633080000 3639170000
41 PI Industries Management Consultancies LLC Plant Health Care Limited (Erstwhile Plant Health care Plc) Subsidiary Loan 0 Exempted 335710000 246780000 583860000
42 PI Industries Management Consultancies LLC Plant Health Care Limited (Erstwhile Plant Health care Plc) Subsidiary Interest received 0 Exempted -14940000 1350000 16680000
43 PI Health Sciences Limited PI Health Sciences NL BV Subsidiary Loan 0 Exempted 188720000 2911140000 21100000
44 PI Health Sciences Limited PI Health Sciences NL BV Subsidiary Any other transaction Conversion of Loan and Outstanding interest into Equity 0 Exempted 3072600000 0 3072600000
45 PI Health Sciences Limited PI Health Sciences NL BV Subsidiary Interest received 0 Exempted 15570000 80520000 610000
46 PI Health Sciences Limited PI Health Sciences NL BV Subsidiary Investment 0 Exempted 657640000 2063530000 2721170000
47 PI Health Sciences Limited PI Health Sciences NL BV Subsidiary Any other transaction Business Support Services 0 Exempted 0 112570000 0
48 PI Health Sciences Limited Archimica S.p.A. Subsidiary Any other transaction Business Support Services 0 Exempted 5990000 0 5990000
49 PI Health Sciences Limited PI Health Sciences LLC, USA Subsidiary Any other transaction Business Support Services 0 Exempted 60550000 0 60550000
50 PI Health Sciences NL BV PI Health Sciences LLC, USA Subsidiary Loan 0 Exempted 74310000 216870000 0
51 PI Health Sciences NL BV PI Health Sciences LLC, USA Subsidiary Any other transaction Loan Repayment 0 Exempted -71800000 0 0
52 PI Health Sciences NL BV PI Health Sciences LLC, USA Subsidiary Any other transaction Conversion of Loan and Outstanding interest into Equity 0 Exempted 239570000 0 0
53 PI Health Sciences NL BV PI Health Sciences LLC, USA Subsidiary Interest received 0 Exempted -1700000 13280000 0
54 PI Health Sciences NL BV PI Health Sciences LLC, USA Subsidiary Investment 0 Exempted 89530000 123060000 212620000
55 PI Health Sciences NL BV Archimica S.p.A. Subsidiary Loan 0 Exempted 164440000 1370380000 0
56 PI Health Sciences NL BV Archimica S.p.A. Subsidiary Any other transaction Conversion of Loan and Outstanding interest into Equity 0 Exempted 1552490000 0 1552490000
57 PI Health Sciences NL BV Archimica S.p.A. Subsidiary Interest received 0 Exempted -6510000 47540000 0
58 PI Health Sciences NL BV Archimica S.p.A. Subsidiary Investment 0 Exempted 559230000 3043200000 3602430000
59 PI Health Sciences NL BV Archimica S.p.A. Subsidiary Any other transaction Business Support Services Exempted 0 115940000 0
60 Archimica S.p.A. PI Health Sciences LLC, USA Subsidiary Any other transaction Business Support Services received 0 Exempted 15100000 0 -15100000
61 PI Life Science Research Limited Solinnos Agro Sciences Private Limited Associate Any other transaction Contribution towards CSR Activities 6000000 Ok 2250000 -1130000 -1550000
62 PI Life Science Research Limited PI Foundation Other related party Any other transaction Contribution towards CSR Activities Ok 580000 0 0
Total value of transaction during the reporting period 8542380000



Text Block

Textual Information(1) This includes Optionally fully convertible debenetures of outstanding balance of 7,500 and transaction of 1000


Format for Disclosing Outstanding Default on Loans and Debt Securities

Sr. No. Particulars Amount Remarks
1. Loans / revolving facilities like cash credit from banks / financial institutions
A Total amount outstanding as on date 0
B Of the total amount outstanding, amount of default as on date 0
2. Unlisted debt securities i.e. NCDs and NCRPS
A Total amount outstanding as on date 0
B Of the total amount outstanding, amount of default as on date 0
3. Total financial indebtedness of the listed entity including short-term and long-term debt 0